Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
Clinical role
Concurrent-reader and post-processing detection support; results are overlaid for radiologist review
Images and patients
CT/CTA · Chest/lungs; pulmonary nodules
Key limitation
Keep in mind: Both lungs must be in the field of view; the device is not intended for use without the original CT series or to differentiate detected regions as benign or malignant. It is an adjunctive concurrent reader, not a substitute for the original study and radiologist interpretation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/lungs; pulmonary nodules Input: Non-contrast chest CT in DICOM format, with both lungs in the field of view and slice thickness less than 3 mm; the comparison matrix lists Canon, GE, Philips, and Siemens CT systems.
Who uses it?Intended users: Radiologist
What does the software produce?Output: Pulmonary-nodule bounding boxes, segmented contours, and measurements including volume, long-axis length, short-axis length, average-axis length, and average Hounsfield-unit value, displayed over the original CT series in a PACS viewer.
What is its most important limitation?Key limitation: Both lungs must be in the field of view; the device is not intended for use without the original CT series or to differentiate detected regions as benign or malignant. It is an adjunctive concurrent reader, not a substitute for the original study and radiologist interpretation.
Clinical takeaway. Clinical role: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
Evidence takeaway. Evidence from the reviewed source record: The FDA packet reports a retrospective MRMC study and standalone evaluation on 300 low-dose chest CT exams from three geographically distinct US regions: 100 with at least one nodule and 200 controls; ground truth was a consensus of three board-certified thoracic radiologists and 15 readers participated. MRMC AUROC increased from 0.768 unaided to 0.835 aided (difference 0.067, p<0.001), LROC from 0.723 to 0.800 (difference 0.076, p<0.001), and reading time fell by 0.76 minutes. Standalone nodule-detection sensitivity was 78.3% (95% CI 71.0-84.8), false-positive rate was 0.76 per case (95% CI 0.64-0.90), and 3D nodule-segmentation Dice was 0.81 (95% CI 0.79-0.83).
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
Non-contrast chest CT in DICOM format, with both lungs in the field of view and slice thickness less than 3 mm; the comparison matrix lists Canon, GE, Philips, and Siemens CT systems.
Pulmonary-nodule bounding boxes, segmented contours, and measurements including volume, long-axis length, short-axis length, average-axis length, and average Hounsfield-unit value, displayed over the original CT series in a PACS viewer.
Both lungs must be in the field of view; the device is not intended for use without the original CT series or to differentiate detected regions as benign or malignant. It is an adjunctive concurrent reader, not a substitute for the original study and radiologist interpretation.
The FDA packet reports a retrospective MRMC study and standalone evaluation on 300 low-dose chest CT exams from three geographically distinct US regions: 100 with at least one nodule and 200 controls; ground truth was a consensus of three board-certified thoracic radiologists and 15 readers participated. MRMC AUROC increased from 0.768 unaided to 0.835 aided (difference 0.067, p<0.001), LROC from 0.723 to 0.800 (difference 0.076, p<0.001), and reading time fell by 0.76 minutes. Standalone nodule-detection sensitivity was 78.3% (95% CI 71.0-84.8), false-positive rate was 0.76 per case (95% CI 0.64-0.90), and 3D nodule-segmentation Dice was 0.81 (95% CI 0.79-0.83).
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA packet reports a retrospective MRMC study and standalone evaluation on 300 low-dose chest CT exams from three geographically distinct US regions: 100 with at least one nodule and 200 controls; ground truth was a consensus of three board-certified thoracic radiologists and 15 readers participated. MRMC AUROC increased from 0.768 unaided to 0.835 aided (difference 0.067, p<0.001), LROC from 0.723 to 0.800 (difference 0.076, p<0.001), and reading time fell by 0.76 minutes. Standalone nodule-detection sensitivity was 78.3% (95% CI 71.0-84.8), false-positive rate was 0.76 per case (95% CI 0.64-0.90), and 3D nodule-segmentation Dice was 0.81 (95% CI 0.79-0.83).
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Synapse Lung Nodule AI regulatory performance study summary
DesignReader Study
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K254075
IndependenceIndependence not established
K254075
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K254075. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast chest CT in DICOM format, with both lungs in the field of view and slice thickness less than 3 mm; the comparison matrix lists Canon, GE, Philips, and Siemens CT systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Retrieves DICOM images from PACS and returns nodule information to PACS, specifically Synapse PACS K190232, as an add-on with FUJIFILM hosting applications. The comparison matrix requires a PACS or DICOM-capable image viewer.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Pulmonary-nodule bounding boxes, segmented contours, and measurements including volume, long-axis length, short-axis length, average-axis length, and average Hounsfield-unit value, displayed over the original CT series in a PACS viewer.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Pulmonary-nodule bounding boxes, segmented contours, and measurements including volume, long-axis length, short-axis length, average-axis length, and average Hounsfield-unit value, displayed over the original CT series in a PACS viewer.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Retrieves DICOM images from PACS and returns nodule information to PACS, specifically Synapse PACS K190232, as an add-on with FUJIFILM hosting applications. The comparison matrix requires a PACS or DICOM-capable image viewer.
Fujifilm Healthcare Americas' Enterprise Imaging security center states that Fujifilm received a SOC 2 Type II report for the previous 12-month period and provides Manufacturer Disclosure Statement for Medical Device Security (MDS2) documentation for Synapse products through its customer portal and a security documentation request form, covering ePHI maintenance/storage/transmission, data backup and removable media, security patch and antivirus installation, remote service access, and ePHI audit logs.
Product family
Checked 2026-10-27
Vendor statement, not an attestation; the SOC 2 report and MDS2 documents were not read (portal/request-gated). Page scope is Fujifilm's Enterprise Imaging (Synapse) line; this entry is a Synapse-named product. Exact-release scope is not established. Not applied to ECHELON (MRI) or Sonosite (ultrasound) entries.
ACR AI Central provides an exact-submission model card for Synapse Lung Nodule AI; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K254075 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.